High-Density Lipoprotein from Chronic Kidney Disease Patients Modulates Polymorphonuclear Leukocytes

Area of Science:

• Nephrology
• Immunology
• Cardiovascular Medicine

Background:

• Uremia alters high-density lipoproteins (HDL), potentially leading to pro-inflammatory features and contributing to chronic inflammation and vascular risk in chronic kidney disease (CKD).
• Polymorphonuclear leukocytes (PMNLs) are implicated in the chronic inflammation observed in CKD patients.

Purpose of the Study:

• To investigate the relationship between HDL from uremic patients and systemic inflammation.
• To determine if uremic HDL interferes with polymorphonuclear leukocyte (PMNL) function.

Main Methods:

• Assessed PMNL apoptosis using morphological features and DNA content.
• Quantified CD11b surface expression via flow cytometry.
• Measured oxidative burst and chemotaxis of PMNLs.

Main Results:

• HDL from CKD and hemodialysis (HD) patients significantly reduced PMNL apoptosis, unlike HDL from healthy subjects.
• Uremic HDL activated phosphoinositide 3-kinase and extracellular-signal regulated kinase pathways, mediating anti-apoptotic effects.
• While healthy HDL reduced CD11b expression, uremic HDL did not. Both increased oxidative burst but did not affect chemotaxis.

Conclusions:

• HDL from uremic patients may contribute to systemic inflammation by modulating PMNL functions, specifically by inhibiting apoptosis and increasing oxidative burst.
• These findings highlight a potential mechanism linking altered HDL in CKD to increased vascular risk through immune cell dysfunction.